8 [56] E. C. M. Cranenburg, C. Vermeer, R. Koos et al., “The circulating inactive form of matrix Gla protein (ucMGP) as a biomarker for cardiovascular calciﬁcation,” Journal of Vascular Research, vol. 45, no. 5, pp. 427–436, 2008. [57] M. M. H. Hermans, C. Vermeer, J. P. Kooman et al., “Under- carboxylated matrix GLA protein levels are decreased in dial- ysis patients and related to parameters of calcium-phosphate metabolism and aortic augmentation index,” Blood Puriﬁca- tion, vol. 25, no. 5-6, pp. 395–401, 2008. [58] G. Schlieper, R. Westenfeld, T. Kr u¨ger et al., “Circulating nonphosphorylated carboxylated matrix Gla protein predicts survival in ESRD,” Journal of the American Society of Nephrol- ogy, vol. 22, no. 2, pp. 387–395, 2011. [59] N. Bucay, I. Sarosi, C. R. Dunstan et al., “Osteoprotegerin- deﬁcient mice develop early onset osteoporosis and arterial calciﬁcation,” Genes and Development, vol. 12, no. 9, pp. 1260– 1268, 1998. [60] S. Jono, Y. Ikari, A. Shioi et al., “Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease,” Circulation, vol. 106, no. 10, pp. 1192–1194, 2002. [61] K. Nitta, T. Akiba, K. Uchida et al., “Serum osteoprotegerin levels and the extent of vascular calciﬁcation in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 19, no. 7, pp. 1886–1889, 2004. [62] K. Nitta, T. Akiba, K. Uchida et al., “The progression of vascular calciﬁcation and serum osteoprotegerin levels in patients on long-term hemodialysis,” American Journal of Kidney Diseases, vol. 42, no. 2, pp. 303–309, 2003. [63] R. C. Shroﬀ, R. McNair, N. Figg et al., “Dialysis accelerates medial vascular calciﬁcation in part by triggering smooth muscle cell apoptosis,” Circulation, vol. 118, no. 17, pp. 1748– 1757, 2008. [64] R. C. Shroﬀ, R. McNair, J. N. Skepper et al., “Chronic mineral dysregulation promotes vascular smooth muscle cell adap- tation and extracellular matrix calciﬁcation,” Journal of the American Society of Nephrology, vol. 21, no. 1, pp. 103–112, 2010. [65] M. S. Razzaque and B. Lanske, “The emerging role of the ﬁbroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis,” Journal of Endocrinology, vol. 194, no. 1, pp. 1–10, 2007. [66] M. S. Razzaque, “The FGF23-Klotho axis: endocrine regula- tion of phosphate homeostasis,” Nature Reviews Endocrinol- ogy, vol. 5, no. 11, pp. 611–619, 2009. [67] B. Lanske and M. S. Razzaque, “Premature aging in klotho mutant mice: cause or consequence?” Ageing Research Reviews, vol. 6, no. 1, pp. 73–79, 2007. [68] D. Sitara, M. S. Razzaque, R. St-Arnaud et al., “Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals,” American Journal of Pathology, vol. 169, no. 6, pp. 2161–2170, 2006. [69] F. Memon, M. El-Abbadi, T. Nakatani, T. Taguchi, B. Lanske, and M. S. Razzaque, “Does Fgf23-klotho activity inﬂuence vascular and soft tissue calciﬁcation through regulating min- eral ion metabolism?” Kidney International, vol. 74, no. 5, pp. 566–570, 2008. [70] M. C. Hu, M. Shi, J. Zhang et al., “Klotho deﬁciency causes vascular calciﬁcation in chronic kidney disease,” Journal of the American Society of Nephrology, vol. 22, no. 1, pp. 124–136, 2011. [71] T. Isakova, O. M. Gutierrez, Y. Chang et al., “Phosphorus binders and survival on hemodialysis,” Journal of the American Society of Nephrology, vol. 20, no. 2, pp. 388–396, 2009. International Journal of Nephrology [72] P. Evenepoel, R. Selgas, F. Caputo et al., “Eﬃcacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis,” Nephrology Dialysis Transplantation, vol. 24, no. 1, pp. 278–285, 2009. [73] W. Qunibi, M. Moustafa, L. R. Muenz et al., “A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calciﬁcation in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2),” American Journal of Kidney Diseases, vol. 51, no. 6, pp. 952–965, 2008. [74] W. N. Suki, R. Zabaneh, J. L. Cangiano et al., “Eﬀects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients,” Kidney International, vol. 72, no. 9, pp. 1130–1137, 2007. [75] M. Ketteler and K. U. Eckardt, “KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention and treatment of chronic kidney disease related mineral and bone disorders (CKD-MBD),” Kidney International, vol. 113, pp. S1–S130, 2009. [76] L. E. Becker, N. Koleganova, G. Piecha et al., “Eﬀect of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice,” American Journal of Physiology, vol. 300, no. 3, pp. F772–F782, 2011. [77] M. Teng, M. Wolf, E. Lowrie, N. Ofsthun, J. M. Lazarus, and R. Thadhani, “Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy,” The New England Journal of Medicine, vol. 349, no. 5, pp. 446–456, 2003. [78] N. Nagano, “Pharmacological and clinical properties of calcimimetics: calcium receptor activators that aﬀord an innovative approach to controlling hyperparathyroidism,” Pharmacology and Therapeutics, vol. 109, no. 3, pp. 339–365, 2006. [79] J. S. Lindberg, B. Culleton, G. Wong et al., “Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study,” Journal of the American Society of Nephrology, vol. 16, no. 3, pp. 800–807, 2005. [80] S. Fishbane, W. B. Shapiro, D. B. Corry et al., “Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 6, pp. 1718–1725, 2008. [81] T. Kawata, N. Nagano, M. Obi et al., “Cinacalcet suppresses calciﬁcation of the aorta and heart in uremic rats,” Kidney International, vol. 74, no. 10, pp. 1270–1277, 2008. [82] N. Koleganova, G. Piecha, E. Ritz, C. P. Schmitt, and M. L. Gross, “A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia,” Kidney International, vol. 75, no. 1, pp. 60–71, 2009. [83] P. Raggi, G. M. Chertow, P. U. Torres et al., “The ADVANCE study: a randomized study to evaluate the eﬀects of cinacalcet plus low-dose vitamin D on vascular calciﬁcation in patients on hemodialysis,” Nephrology Dialysis Transplantation, vol. 26, no. 4, pp. 1327–1339, 2011. [84] K. Lomashvili, P. Garg, and W. C. O’Neill, “Chemical and hormonal determinants of vascular calciﬁcation in vitro,” Kidney International, vol. 69, no. 8, pp. 1464–1470, 2006. [85] T. Weinreich, J. Passlick-Deetjen, and E. Ritz, “Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial,” American Journal of Kidney Diseases, vol. 25, no. 3, pp. 452–460, 1995.